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An outbreak of multidrug-resistant Pseudomonas aeruginosa (MDRPA) infections in a university hospital is described. Pheno-
typic and genotypic analysis of 240 isolates revealed that 152 patients, mainly in the intensive care unit (ICU), were colonized or
infected withMDRPA, the majority with O11. All metallo--lactamase (MBL)-positive isolates carried the blaVIM-2 or blaVIM-1
gene. One or more type III secretion system toxin genes were detected in most isolates. Five dominant pulsed-field gel electro-
phoresis (PFGE) types were characterized, associated with ST235, ST111, ST253, ST309, and ST639.
Pseudomonas aeruginosa is an opportunistic pathogen causingsevere invasive disease in critically ill and immunocompro-
mised patients. Because of its ubiquitous nature, ability to survive
in moist environments, and innate resistance to many antibiotics
and antiseptics, it constitutes a common pathogen in hospitals,
particularly in intensive care units (ICUs). Its treatment is a ther-
apeutic challenge because of the intrinsic resistance and the ability
to easily acquire resistance determinants (1). Multidrug-resistant
P. aeruginosa (MDRPA) infections occur mainly in ICU patients
(2). The prevalence and epidemiology of MDRPA have become
the focus of numerous single- andmulticenter surveillance studies
(3). The large number of secreted and cell-associated virulence
factors is implicated in the pathogenesis of severe infections. The
type III secretion system (TTSS), a complex of three proteins, is
associated with lung injury, sepsis, and a 6-fold-greater risk of
mortality, constituting an important virulence determinant (4, 5).
Results on emergence and spread of MDRPA isolates in the Uni-
versity Hospital of Patras (UHP) and their phenotypic and geno-
typic characteristics are presented in this study.
During a 2-year period, a total of 952 P. aeruginosa isolates
were recovered from 430 patients hospitalized in our tertiary-care
hospital, located in southwesternGreece, with 700 acute-care beds
and about 100,000 admissions annually. Two hundred and forty,
the first 10 fromeverymonthwith no replicate isolates (one isolate
per patient), from different wards and a variety of clinical speci-
mens, including true infections and carriage, were selected for
further study. Colonizing isolates were recovered from stool and
respiratory tract specimens from patients without signs of infec-
tion.
P. aeruginosa was identified by standard methods. Colonizing
(83) and infection-related (157) isolates were compared for their
phenotypes and genotypes. For further analyses, isolates were di-
vided into two groups: those recovered from ICU patients (92)
and those from non-ICU patients (148).
Antibiotic susceptibility testing was performed by the agar disk
diffusion method against antipseudomonal agents according to
CLSI guidelines (6). All isolates resistant to at least three classes of
antibiotics were defined as MDRPA (7). The MIC of colistin was
determined by the Etest (AB Biodisk, Solna, Sweden). All imi-
penem-nonsusceptible (IMP-NS) isolates (MICs  1 mg/liter)
were examined for metallo--lactamase (MBL) production using
the Etest MBL assay (AB Biodisk).
Serotyping was performed by 16 monovalent antisera (Bio-
Rad, Marne’s-la-Coquette, France) as previously described (8).
Among the IMP-NS isolates, the blaVIM gene was detected us-
ing the multiplex PCR-enzyme-linked immunosorbent assay
(ELISA) system (hyplex MBL ID PCR module Hyb-module test
system; BAG Health Care, Lish, Germany) (9). Types of blaVIM
genes were identified by sequencing analysis among selected bla-
VIM-positive strains after comparison with a data bank (http:
//blast.ncbi.nlm.nih.gov/Blast.cgi). In all isolates, TTSS genes
(exoS, exoT, exoU, exoY) were investigated by PCR (10).
Cloneswere defined by pulsed-field gel electrophoresis (PFGE)
of speI (Roche, Penzberg, Germany) DNA digests. Banding pat-
terns were compared by Fingerprinting II Informatics Software
(Bio-Rad, Berkeley, California), and clones were defined accord-
ing to already established criteria (11). A dendrogram comparing
molecular weights of strains’ DNA fragments to those from a pre-
vious collection by using FPQuest software (Bio-Rad; catalog
number 1709300) was computed. Clustering was based on75%
similarity. Selected strains of the main PFGE types were charac-
terized by multilocus sequence typing (MLST) (http://pubmlst
.org/paeruginosa).
Pearson’s chi-square test was used to evaluate the differences in
the frequencies of variables in ICU and non-ICU wards, con-
ducted by PASW Statistics 18, release version 18.0.0 (SPSS, Inc.,
Chicago, IL; www.spss.com). Results were considered significant
at a P value of0.05.
A comparison of nonsusceptibility to antibiotics between ICU
and non-ICU P. aeruginosa isolates is presented in Fig. 1. All iso-
lates were susceptible to colistin (MICs 2 mg/liter). During the
study period, a high frequency of MDRPA was detected (152/240
isolates; 63.33%), mainly in ICU isolates (Table 1). There were no
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statistically significant differences in antibiotic resistance patterns
between infecting and colonizing isolates. A blaVIM gene was de-
tected in all 49 MBL-positive isolates. No statistically significant
difference was observed between ICU and non-ICU isolates
(17.4% versus 22.3%, respectively) (Table 1). The majority of the
isolates carried blaVIM-2, while only three strains carried the
blaVIM-1 gene.
Serogroup O11 predominated in the ICU compared to all
other wards (Table 1) as well as among MDRPA isolates (75%
[63/84] in the ICU and 57.4% [39/68] in non-ICU wards [P 
0.021]).
The majority of isolates (227/240; 94.6%) carried one or more
toxin genes, while only 79 (33%) carried all four. Ninety-one iso-
lates (91/240; 37.9%) carried both exoU and exoS genes. exoUwas
detected mainly among ICU patients, while exoS from non-ICU
patients was found with a statistically higher frequency (Table 1).
Also, the exoS gene was statistically significant among infection
isolates compared to carriage (53.50% versus 31.32%; P 0.001).
PFGE exhibited five predominant pulsotypes (Table 1; Fig. 2).
PFGE type a strains were identified as ST235; type b strains carry-
ing the blaVIM-1 gene belonged to ST111, while those carrying
blaVIM-2 were identified as ST235; type c strains were ST253 and
type d strains were ST235, while those of type s were classified as
ST309 and ST639. The remaining isolates were classified into 78
PFGE types including 1 to 3 strains each. Polyclonality was ob-
servedmainly among non-ICU strains (Table 1). Common clones
among infecting and colonizing isolates were identified. The
MDRPA strains, includingMBL-positive strains, belongedmainly
to pulsotypes a and d, both characterized as ST235.
Surveillance studies have documented increases in the fre-
quency of outbreaks, especially in ICU infections caused by strains
resistant to multiple classes of antibiotics (12, 13). P. aeruginosa
was related to 8% of total infections and carriage during the study
period, while among ICU patients, an outbreak occurred due to
the spread of one main clone (ST235) of MDRPA. In our hospital
setting, MDRPA accounted for 49.5% of P. aeruginosa infections
before the present study, reached 63.3% during the studied pe-
riod, and dropped afterwards to 38.5%.
A higher prevalence of MBL production was observed among
IMP-NS P. aeruginosa isolates (33%) than in other studies from
Greece and other European countries (14, 15). All MBL-positive
isolates in the present study carried the blaVIM gene and were
spread in all hospital wards, especially among non-ICU patients
(Table 1). VIM-type MBLs are predominant in Europe, particu-
larly in the Mediterranean region, and have been associated with
large outbreaks of MDRPA (3, 16, 17). More specifically, blaVIM-2
FIG 1 Percentages of P. aeruginosa isolates nonsusceptible to various classes of antibiotics among ICU and non-ICU patients. Antipseudomonas penicillins
include azlocillin, carbenicillin, piperacillin, and ticarcillin-clavulanic acid. Aminoglycosides include amikacin, netilmicin, and tobramycin.
TABLE 1 Characteristics of ICU and non-ICU P. aeruginosa isolatesa
Characteristic
No. (%) of isolates with each
characteristic
P value
ICU isolates
(n 92)
Non-ICU isolates
(n 148)
MDRPA 84 (91.3) 68 (46.0) 0.001
MBL positive 16 (17.4) 33 (22.3) 0.359
Serotype O11 68 (73.9) 50 (33.8) 0.001
blaVIM 16 (17.4) 33 (22.3) 0.359
exoS 25 (27.2) 86 (58.1) 0.001
exoT 76 (82.6) 116 (78.4) 0.427
exoU 83 (90.2) 118 (79.7) 0.032
exoY 81 (88.0) 125 (84.5) 0.438
Clone a (ST235) 59 (64.1) 22 (14.9) 0.001
Clone d (ST235) 15 (16.3) 18 (12.2) 0.365
Clone b (ST111 or ST235) 3 (3.3) 7 (4.3) 0.745
Clone c (ST253) 1 (1.0) 5 (3.4) 0.410
Clone s (ST309 or ST639) 0 (0.0) 6 (4.0) 0.084
All other clones 14 (15.2) 90 (60.8) 0.001
a ICU, intensive care unit; MDRPA, multidrug-resistant P. aeruginosa; MBL,
metallo--lactamase.
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is the most frequent type in southern European countries (3),
while in Greece, blaVIM-17, a variant of blaVIM-2, was identified in
another outbreak (16).
Serotype O11 is common in hospital outbreaks and associated
with multidrug resistance (2, 12), as is also shown in the present
study.
In our collection, 94.6% of P. aeruginosa isolates carried one or
more TTSS genes, as reported elsewhere (18). exoS was more fre-
quent in isolates from urinary tract and wound infections from
non-ICU patients, a finding that is in accordance with those by
other investigators (18). exoU was associated with serotype O11,
as reported also by Faure et al. (4), and detected mainly among
ICU isolates (P 0.032). Expression of exoU correlates with acute
cytotoxicity and accelerated lung injury playing a role in the de-
velopment of septic shock in ICU high-risk patients (18, 19).
MDRPA strains belonged mainly to PFGE types a and d of
serotype O11 and ST235. A comparison of the recently identified
clones with previous ones revealed no relationship (Fig. 2) (20).
Studies have reported clonally related nosocomial outbreaks of
MDRPA producing IMP-13 MBL (13) and panantibiotic-resis-
tant P. aeruginosa in ICUs (12). The observation that the majority
of pulsotype d strains (ST235) carry the blaVIM-2 gene reinforces
the theory that clonal spread may have played a role in the out-
break of IMP-NS P. aeruginosa. blaVIM gene spread was identified
among clonally related strains in the last decade (1, 17, 21).
The observation thatmost carriage isolates belonged to the two
predominant PFGE types a (38/83) and d (11/83) and to the same
clone, ST235, indicates that colonization during ICU hospitaliza-
tion contributes to infection and spread to other wards. Clinical
isolates of ST235 (serotypeO11) harboring acquired-lactamases
have been reportedworldwide (22).P. aeruginosa ST235 (serotype
O11) strains from bloodstream infections were among the three
predominant epidemic clones in the Czech Republic (22).
This study describes a clonal outbreak during a 2-year period
of MDRPA serotype O11 of the ST235 clone in a university hos-
pital which occurred mainly in the ICU. P. aeruginosa clearly rep-
resents one of the most challenging pathogenic bacteria, since
MDRPA isolates spread clonally quite frequently. Themonitoring
of MBL- and exotoxin gene-carrying isolates has epidemiological
significance in the identification of drug-resistant and virulent P.
aeruginosa isolates, especially in high-risk patients. Our work
shows the need for clonal identification, since MDRPA outbreaks
require targeted infection control measures.
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